Biotech News

Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel

Humacyte (HUMA)HumacyteCompany update

– Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel. DURHAM, N.C., Nov.

Related news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

Stock data

Close
0.54 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States